Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir

✍ Scribed by H.L. Zaaijer; R.B. Takkenberg; C.J. Weegink; S.P.H. Rebers; S. Menting; H.W. Reesink; J. Schinkel; R. Molenkamp

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 134 KB
• Volume: 81
• Category: Article
• ISSN: 0146-6615
• DOI: 10.1002/jmv.21401

✦ Synopsis

Abstract

Serial monotherapy and add‐on regimes for treatment of chronic hepatitis B virus (HBV) infection may induce the accumulation of viral resistance mutations in patients, reducing the options for ongoing viral suppression. The induction of antiviral resistance by serial application of polymerase inhibitors does not necessarily imply that the subsequent combined use of the drugs will fail. Some HIV strains resistant to one polymerase inhibitor show increased susceptibility to another polymerase inhibitor. After failure of sequential lamivudine and adefovir monotherapy, two patients with hepatitis B changed to treatment with lamivudine plus adefovir and had renewed suppression of HBV. To study the mutational history of resistant HBV subpopulations in the two patients, a part of the HBV polymerase gene was amplified, cloned, sequenced, and analyzed for the presence of mutations, in sequential plasma samples. In both patients serial monotherapy caused the replacement in all HBV clones of wild‐type virus by classical lamivudine resistant mutants (L180M and M204V/I), which were replaced subsequently by adefovir resistant mutants (A181V and N236T). When finally lamivudine was added to adefovir, the A181V adefovir mutation persisted in all clones and lamivudine‐related mutations did not reappear. During 18 months of combination therapy, HBV‐DNA levels decreased 10,000, respectively, 1,000‐fold, despite the earlier resistance to lamivudine and adefovir. Although clinically insufficient, this effect indicates that HBV polymerase resistance mutations may be antagonistic, which is relevant if chronic HBV infection is to be treated by a combination of polymerase inhibitors. J. Med. Virol. 81:413–416, 2009. © 2009 Wiley‐Liss, Inc.